Overview
The landscape of treatment options for patients with advanced non–small cell lung cancer (advNSCLC) has significantly expanded with the advent of targeted therapies, particularly for those harboring ROS1 and NTRK rearrangements. However, the scarcity of comprehensive biomarker testing data limits the understanding of disease burden and economic impact in these patients. This investigation aims to delineate the prevalence, incidence, and clinical attributes of ROS1 and NTRK-positive patients who underwent thorough genomic profiling in real-world clinical scenarios.
Why this matters
This study provides essential insights into advNSCLC patients with ROS1 and NTRK rearrangements, revealing prevalence rates, diagnostic timelines, and distinct patient profiles. Treatment patterns, such as prevalent use of targeted therapy for ROS1-positive individuals and chemotherapy and immunotherapy for NTRK-positive patients, hold significant implications for clinical decision-making and patient care. By advancing our understanding of advNSCLC management in patients with ROS1 and NTRK rearrangements, this research informs current clinical practice and guides future efforts to optimize patient outcomes within this population.
View the abstract on the ISPOR website
More from Flatiron Health at ISPOR US 2024
Read about Flatiron's accepted research and presence at ISPOR US.
